Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00648024 · ClinicalTrials.gov registry record · Phase 1
Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00648024 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT00648024, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dose administration under fasting conditions.
Interventions
- DRUG Anagrelide Hydrochloride Capsules 1 mg
- DRUG Agrylin® Capsules 1 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2003-01 |
| Est. Completion | 2003-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00648024
The ClinicalTrials.gov registry entry for NCT00648024 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anagrelide Hydrochloride Capsules 1 mg is the first listed.
NCT00648024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00648024 about?
NCT00648024 is a clinical study titled "Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg". The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dose administration under fasting conditions.
What is the current status of trial NCT00648024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2003-01. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00648024?
The interventions under investigation include: Anagrelide Hydrochloride Capsules 1 mg (DRUG), Agrylin® Capsules 1 mg (DRUG).
Who is sponsoring clinical trial NCT00648024?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.